Psychopharmacological approaches to the organic brain syndrome.
D000368:Aged; D000375:Aging; D000544:Alzheimer Disease / Q000175:diagnosis; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003071:Cognition; D003704:Dementia / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D003937:Diagnosis, Differential; D006801:Humans; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000502:physiology; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000523:psychology; D018377:Neurotransmitter Agents / Q000502:physiology; D010889:Piracetam / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D013268:Stimulation, Chemical; D014481:United States; D014665:Vasodilator Agents / Q000627:therapeutic use
D009419:Nerve Tissue Proteins; D018377:Neurotransmitter Agents; D011619:Psychotropic Drugs; D014665:Vasodilator Agents; D010889:Piracetam